IPG Photonics' margin recovery looks different without tariff refunds

IPG Photonics increased sales, earned more money and reported a higher gross margin in the September quarter. Tariff refunds make an important difference to that last comparison.

Research by Ticker Byline shows that removing the disclosed refund benefits from both years reverses the direction of the margin change. Our calculation puts gross margin at about 39.0%, against 39.3% a year earlier, rather than the reported increase to 40.7% from 39.5%.

That leaves a more specific question behind the recovery: can stronger demand lift profitability as the factory cost burden grows?

Sales growth is real

Revenue rose 15% to $287.5 million. Industrial applications grew 12%, helped by welding and additive manufacturing. Advanced applications grew 33%, with semiconductor and defense demand providing support.

GAAP operating income increased to $20.8 million from $7.9 million, and net income rose to $20.3 million from $7.5 million. The business improved beyond the change in refund benefits alone.

Adjusted EPS reached 61 cents, a penny above the top of August's forecast. Adjusted EBITDA, a profit measure that removes interest, taxes, depreciation, amortization and selected other items, was $51.5 million against a $35 million to $51 million forecast.

What changes when the refunds come out

The accounting note records $5.8 million of tariff refund benefits and $802,000 of offsetting charges in cost of sales. That gives a net benefit of about $5 million. The comparable quarter last year included a smaller $550,000 benefit.

We removed each year's benefit from its gross profit and divided the result by sales. That produces the 39.0% versus 39.3% comparison. It measures the margin after production costs, before research, selling and administrative expenses.

IPG keeps these refunds in its published adjusted results. Its release identifies them as one reason for the margin improvement, alongside lower product costs. The filing also reports an $11.1 million increase in manufacturing costs left uncovered by production activity.

The refund-excluded margin improved modestly from the June quarter. The comparison points to a year-over-year cost challenge within a growing business, rather than a sequential deterioration.

The next quarter has another cost to absorb

IPG expects fourth-quarter sales of $265 million to $295 million and adjusted EPS of 30 cents to 60 cents. Its adjusted gross-margin range of 37% to 40% sits below the September quarter's 41%.

A separate October property-sale plan is expected to bring a roughly $25 million noncash pretax impairment charge in Q4. The properties are expected to be sold in 2027.

The forecast excludes the pending Lumibird Medical acquisition, agreed in September for €300 million in cash plus a possible €50 million earnout. IPG expects it to close in Q4 and expand its medical business.

Cash and investments totaled about $926 million at September 30, leaving substantial funding capacity before that purchase. The next results will show how much sales growth reaches the margin while the company reshapes its operations. The IPG Photonics company profile tracks the financial results, acquisition and disposal plans.